Ann: Director Appointment/Resignation, page-109

Hey B3R, the comment about ‘ This business is not done yet by any means, ...’ has its foundation in its science, science/IP that is arguably top notch.

That SB, committed to a 20% stake in Admedus would further support this, imo.

‘Addtional significant investors have recently put money in the pot’, could you clarify that mate?, from previous CR it seems only SB have come to the table, at a very hefty discount!, question of why not at 30 cents??

Absolute no brainer that SB here to make money either by adding value and ‘flipping’ or taking Admiedus ‘private’

In regards to the ‘blame’ game the buck most definitely stops at WP, imo, he may have end up being out of his dept; failed forecasts, comment on no more CR’s, disaster (?) of a second CR after the previous one 3 months ago previous, has arguably led to a 20% stake in Admedus sold for a pittance of 10 and 13.5 cents, far below ‘true value’ (?), 30 cents a far more realistic value (?).

Not sure what your comment ‘it takes two to tango means’, WP is suppose to be the end all, be all, no disrespect meant,  but on a hefty salary for being the Man in charge, with that comes responsibility for the success OR failure of this company.

Potential future investors (?) would/should be aware of DD and disregard ‘speculation’ by HC posters 100%, especially during the hype of the earlier years.

Questioning where this company is at or will be, is not ‘throwing rocks’ at this investment, in actual fact maybe ‘more’ rocks should have been chucked at the start of this ‘fairy tale’.

WP, himself, stated that successful IP needs to be married up WITH successfull commercialisation, this, imo, has lagged significantly.

That the science/IP is, arguably, right up there, who will reap the most benefit?, on the AI division and the CardioCel tech platform?

We would ‘hope’ to have our capital ‘returned’ with maybe a modest return at the best, that Is Life.